This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

TSC Ratings' Updates: KV Pharmaceutical

KV Pharmaceutical (KV.A) has been upgraded from hold to buy. KV Pharmaceutical Company engages in the development, manufacture, acquisition, marketing and sale of branded and generic/nonbranded prescription pharmaceutical products. The company offers its products in various dosage forms, including tablets, capsules, creams, liquids and ointments.

The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings-per-share growth, compelling growth in net income, notable return on equity and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

The revenue growth came in higher than the industry average of 14.2%. Since the same quarter one year prior, revenue rose by 30.2%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.

KV Pharmaceutical significant earnings per share improvement in the most recent quarter compared with the same quarter a year ago. The company has demonstrated a pattern of positive earnings-per-share growth over the past two years. We believe that this trend should continue. During the past fiscal year, KV Pharmaceutical increased its bottom line by earning $1.53 vs. 99 cents in the prior year. This year, the market expects an improvement in earnings ($1.55 vs. $1.53).

The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the pharmaceuticals industry. The net income increased by 102.2% when compared with the same quarter one year prior, rising from $6.20 million to $12.54 million.
1 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
PXP $0.00 0.00%
SPG $178.72 1.67%
TTI $6.16 2.84%
AAPL $125.69 -0.25%
FB $87.22 -0.38%

Markets

DOW 17,776.91 +93.33 0.53%
S&P 500 2,081.34 +12.58 0.61%
NASDAQ 4,997.4590 +5.5190 0.11%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs